Peptides vs SARMs vs TRT
Peptides are short chains of amino acids that signal through specific receptors. SARMs are non-steroidal molecules that selectively bind the androgen receptor and remain investigational. TRT is testosterone-replacement therapy supervised by a clinician for clinically diagnosed hypogonadism. The three differ in mechanism, oversight, and regulatory status.
What's being compared
Short amino-acid signaling molecules used across many clinician-directed protocols.
Selective androgen receptor modulators; remain investigational and are not FDA-approved.
Testosterone-replacement therapy with FDA-approved options for clinically diagnosed hypogonadism.
Side-by-side comparison
| Attribute | Peptides | SARMs | TRT |
|---|---|---|---|
| What it is | Short amino-acid sequences; many distinct molecules with distinct targets. | Synthetic non-steroidal compounds that selectively bind the androgen receptor. | Endogenous hormone replacement using bioidentical or pharmaceutical testosterone. |
| How it acts | Signal through specific peptide receptors (e.g. GHRH-R, GHS-R, GLP-1R, melanocortin). | Bind the androgen receptor with tissue-selective signaling profiles in pre-clinical models. | Replaces deficient testosterone to restore physiological levels under clinician supervision. |
| Regulatory status | Mixed: some have FDA-approved finished products; many are compounded preparations. | Investigational. No SARM is FDA-approved for human use; many are explicitly disallowed in sport. | FDA-approved finished products exist for clinically diagnosed hypogonadism. |
| Clinical oversight | Clinician-directed; compounded formulations require a patient-specific prescription. | Lack the clinician-prescribed pharmaceutical pathway TRT and many peptides have. | Clinician-directed with required diagnosis, ongoing labs, and monitoring. |
| Labs typically considered | Vary by peptide; commonly include CBC, CMP, IGF-1, lipid panel as clinically indicated. | No standardized clinical lab pathway because the class is investigational. | Total testosterone (typically morning, repeated), free testosterone, hematocrit, PSA, estradiol. |
| Routes | Subcutaneous, oral, nasal, troche, or topical depending on molecule. | Oral preparations are most common in research literature. | Intramuscular, subcutaneous, transdermal, or pellet routes per FDA-approved labeling. |
| Typical dosing form | Form depends on molecule: weekly subcutaneous injection, daily injection, oral troche, nasal spray, or topical preparation. | Oral capsule or liquid preparations dominate the research literature; no standardized clinical dosing form. | Weekly to biweekly intramuscular or subcutaneous injection, daily transdermal, or extended pellet implant per the FDA-approved labeling chosen by the clinician. |
| Evidence base | Mixed: some peptides have substantial published trial evidence; others rely largely on pre-clinical or early clinical literature. | Limited published human safety and efficacy literature; the category remains investigational. | Decades of published clinical literature on testosterone replacement in clinically diagnosed hypogonadism. |
| Typical clinician use case | Considered by clinicians when a specific signaling pathway (GH axis, GLP-1, tissue support, etc.) fits the clinical question. | Not part of the Regen Therapy catalog; clinicians evaluating these contexts typically consider TRT or peptide alternatives instead. | Considered when labs and symptoms confirm clinically diagnosed hypogonadism and the patient is appropriate for hormone replacement. |
| Regen Therapy availability | Available as multiple clinician-directed protocols across the catalog. | Not part of the Regen Therapy catalog. | Available as testosterone protocols including the RT-CS-03 pellet option, after clinician evaluation. |
Which one might fit?
Use the framings below as orientation only. The right therapy is determined by your prescribing clinician based on history, lab work, and the specifics of your situation.
TRT is the FDA-approved pathway for clinically diagnosed hypogonadism, used under clinician supervision with required labs.
Peptides are the most diverse of the three categories; the right molecule depends on the specific clinical question.
SARMs are investigational and are not part of the Regen Therapy catalog. A clinician evaluation is the right place to discuss alternatives.
Talk to a clinician about which fits
Every Regen Therapy protocol is reviewed by a licensed clinician and dispensed by Wells Pharmacy Network only after evaluation. Start with a brief intake to see what makes sense for your situation.
Frequently asked questions
Are peptides, SARMs, and TRT comparable?
They are different categories. Peptides are amino-acid signaling molecules; SARMs are investigational synthetic compounds that bind the androgen receptor; TRT is hormone replacement with FDA-approved options. The three are not interchangeable.
Are SARMs FDA-approved?
No SARM is FDA-approved for human use. The category remains investigational, and many SARMs are explicitly disallowed in regulated sport.
Is TRT a peptide?
No. Testosterone is a steroid hormone, not a peptide. TRT replaces a deficient hormone under clinician supervision; peptides signal through specific peptide receptors.
Does Regen Therapy offer SARMs?
No. The Regen Therapy catalog does not include SARMs. The catalog focuses on clinician-directed peptide, GLP-1, hormone, and regenerative protocols.
How does a clinician decide which category to consider?
It starts with the clinical question — symptoms, history, lab work, and goals — and from there a clinician evaluates whether any therapeutic pathway is appropriate, and which one fits the situation.
Are compounded peptides FDA-approved?
Compounded peptides are not FDA-approved finished products. They are prepared by 503A or 503B compounding pharmacies on a patient-specific prescription when clinically appropriate.